Navigation Links
Syndax Pharmaceuticals' Entinostat in Combination Shows Activity in Breast Cancer
Date:12/10/2010

rofessor of oncology and pathology at Johns Hopkins University School of Medicine. "With chemotherapy as the primary treatment option for triple negative breast cancer patients, these results are encouraging that this patient population could have another treatment option in the future."

For more Information regarding the SABCS presentations please visit the SABCS website at http://www.sabcs.org/ProgramSchedule/ScheduleGlance.asp.

About Entinostat Entinostat is an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. Entinostat is currently being investigated in multiple phase 2 clinical studies: in advanced breast cancer in combination with aromatase inhibitors; in combination with erlotinib in metastatic lung cancer and as a single agent in Hodgkin's lymphoma. Entinostat also is being studied in advanced non-small-cell lung cancer and in advanced colorectal cancer in combination with azacitidine under a Cooperative Research and Development Agreement (CRADA) with the NCI.

Research has shown that HDACs are involved in the expression of various genes, such as the estrogen receptor, that regulate cell growth, differentiation and apoptosis. Such genes are frequently silenced in cancer cells through the over-expression of enzymes including HDACs. HDACs are therefore recognized as promising targets for cancer treatment. Further, studies have demonstrated that HDAC inhibition can significantly enhance anti-cancer activity when used in combination with a broad range of anti-cancer agents. The potential therefore exists to overcome tumor resistance to targeted agents.

About Syndax Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of pati
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
2. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
3. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
4. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
5. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
6. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
7. Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia
8. Reportlinker Adds Global Generic Pharmaceuticals Industry Report
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Data from Phase 2 Study of Alder Biopharmaceuticals Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
11. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , August 1, 2014 ... Market by Type (Traditional Wound Closure, Anti infective), Basic ... (Artificial Skin & Skin Substitutes), Pressure Relief Devices, ... MarketsandMarkets, the global Wound Care Market is expected to ... in 2014, growing at a CAGR of 3.2% ...
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
... AUSTIN, Texas, May 22, 2012 SmallCapVoice.com, Inc. ... Medical Marijuana, Inc. (PINKSHEETS: MJNA) is now available. ... . Recent company activity and highlights: ... approximately $1.21 million on gross revenues of $1.79 ...
... Laboratory, Inc. (HDL, Inc.), a CAP accredited leader in ... with a non-restricted educational grant to further its mission ... the United States. In addition to the grant, HDL, ... of the 2012 Annual Scientific Sessions in Scottsdale, Arizona ...
Cached Medicine Technology:Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 2Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 3Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 4Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona 2
(Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
(Date:8/1/2014)... School of Medicine in St. Louis helps explain why ... are more harmful than similar tumors in females. For ... diagnosed twice as often in males, who suffer greater ... long. , The researchers found that retinoblastoma protein (RB), ... less active in male brain cells than in female ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... obese and work in manufacturing jobs may have significantly less endurance ... a study of 32 people -- half were obese, half were ... times that were about 60 percent longer. Obesity also was ... Being older -- 50 to 65 years of ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Almost 140 people ... transportation in the United States. But there ... catastrophes, Dawne Gardner, injury prevention coordinator at Cincinnati ... said in a medical center news release. ... to school, it,s important for parents and children ...
(Date:8/1/2014)... MN (PRWEB) August 01, 2014 Summer is ... are most active during the summer, and they can be ... Minnesota is ready to help all their customers get rid ... between 3,000 and 6,000 eggs in the summer, which is ... to live in tall grass and woodland areas and carry ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2
... was honored for ecommerce expertise when President Michael Del Chiaro was ... the highly respected Entrepreneur magazine. , ... Fort Scott, ... for the interview based on his proven success in building a ...
... Feature ,Leave It To Beaver, Star Jerry MathersJACKSON, Miss., ... Express, bus tour will be stopping in Mississippi the ... state in order to help uninsured and financially-struggling Mississippians ... free or nearly free. With the unemployment rate in ...
... March 5 Ranbaxy Pharmaceuticals Inc. (RPI), a ... announced today that RLL has received approval from ... and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + ... The Application for the drug was submitted by ...
... every day for six months were able to increase the ... their erectile function by up to 36%, according to an ... BJU International . , Researchers from San Giovanni Battista Hospital ... this treatment could provide a viable alternative to surgery, as ...
... March 4, 2009Overweight children and adolescents, with the active ... weight by following the Seven Steps to Success described ... a journal published by Mary Ann Liebert, Inc. ... , A team of experts that includes ...
... BioFortis wins another award for its Labmatrix(TM) ... institutional clients worldwide for translational research, biomarker ... 5 /PRNewswire/ -- BioFortis, Inc., ... used by pharmaceutical and institutional clients, today ...
Cached Medicine News:Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2Health News:7 steps to successful child and adolescent weight loss 2Health News:BioFortis Wins Best Product Award in Discovery Informatics at the 2009 Molecular Medicine Tri-Conference 2
... ready-to-use solutions ideal for a wide range ... prepared with 18 megOhm water, filtered using ... sterile bottles., Reliable - Manufactured according ... lot-to-lot consistency. , High Quality - ...
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
Medicine Products: